141 related articles for article (PubMed ID: 27194209)
1. Clinicopathogenomic analysis of mismatch repair proficient colorectal adenocarcinoma uncovers novel prognostic subgroups with differing patterns of genetic evolution.
Braxton DR; Zhang R; Morrissette JD; Loaiza-Bonilla A; Furth EE
Int J Cancer; 2016 Oct; 139(7):1546-56. PubMed ID: 27194209
[TBL] [Abstract][Full Text] [Related]
2. FBXW7 mutation analysis and its correlation with clinicopathological features and prognosis in colorectal cancer patients.
Chang CC; Lin HH; Lin JK; Lin CC; Lan YT; Wang HS; Yang SH; Chen WS; Lin TC; Jiang JK; Chang SC
Int J Biol Markers; 2015 Feb; 30(1):e88-95. PubMed ID: 25450649
[TBL] [Abstract][Full Text] [Related]
3. ERBB2 gene as a potential therapeutic target in small bowel adenocarcinoma.
Laforest A; Aparicio T; Zaanan A; Silva FP; Didelot A; Desbeaux A; Le Corre D; Benhaim L; Pallier K; Aust D; Pistorius S; Blons H; Svrcek M; Laurent-Puig P
Eur J Cancer; 2014 Jul; 50(10):1740-1746. PubMed ID: 24797764
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathologic characteristics of FBXW7-mutated colorectal adenocarcinoma and association with aberrant beta-catenin localization.
Escobar D; Bushara O; Sun L; Liao J; Yang GY
Hum Pathol; 2022 Jan; 119():51-58. PubMed ID: 34717891
[TBL] [Abstract][Full Text] [Related]
5. Increased incidence of FBXW7 and POLE proofreading domain mutations in young adult colorectal cancers.
Kothari N; Teer JK; Abbott AM; Srikumar T; Zhang Y; Yoder SJ; Brohl AS; Kim RD; Reed DR; Shibata D
Cancer; 2016 Sep; 122(18):2828-35. PubMed ID: 27244218
[TBL] [Abstract][Full Text] [Related]
6. Intratumoral budding as a potential parameter of tumor progression in mismatch repair-proficient and mismatch repair-deficient colorectal cancer patients.
Lugli A; Vlajnic T; Giger O; Karamitopoulou E; Patsouris ES; Peros G; Terracciano LM; Zlobec I
Hum Pathol; 2011 Dec; 42(12):1833-40. PubMed ID: 21664647
[TBL] [Abstract][Full Text] [Related]
7. Identification of molecular targets in vulvar cancers.
Palisoul ML; Mullen MM; Feldman R; Thaker PH
Gynecol Oncol; 2017 Aug; 146(2):305-313. PubMed ID: 28536037
[TBL] [Abstract][Full Text] [Related]
8. Epithelial ovarian cancer: rationale for changing the one-fits-all standard treatment regimen to subtype-specific treatment.
Despierre E; Yesilyurt BT; Lambrechts S; Johnson N; Verheijen R; van der Burg M; Casado A; Rustin G; Berns E; Leunen K; Amant F; Moerman P; Lambrechts D; Vergote I;
Int J Gynecol Cancer; 2014 Mar; 24(3):468-77. PubMed ID: 24557434
[TBL] [Abstract][Full Text] [Related]
9. Panel gene profiling of small bowel adenocarcinoma: Results from the NADEGE prospective cohort.
Aparicio T; Svrcek M; Henriques J; Afchain P; Lièvre A; Tougeron D; Gagniere J; Terrebonne E; Piessen G; Legoux JL; Lecaille C; Pocard M; Gornet JM; Zaanan A; Lavau-Denes S; Lecomte T; Deutsch D; Vernerey D; Puig PL
Int J Cancer; 2021 Apr; 148(7):1731-1742. PubMed ID: 33186471
[TBL] [Abstract][Full Text] [Related]
10. Next-Generation Sequencing of Matched Primary and Metastatic Rectal Adenocarcinomas Demonstrates Minimal Mutation Gain and Concordance to Colonic Adenocarcinomas.
Crumley SM; Pepper KL; Phan AT; Olsen RJ; Schwartz MR; Portier BP
Arch Pathol Lab Med; 2016 Jun; 140(6):529-35. PubMed ID: 26536055
[TBL] [Abstract][Full Text] [Related]
11. High Frequency of KRAS Codon 146 and FBXW7 Mutations in Thai Patients with Stage II-III Colon Cancer.
Korphaisarn K; Pongpaibul A; Roothumnong E; Pongsuktavorn K; Thamlikitkul L; Anekpuritanang T; Poungvarin N; Thongnoppakhun W; Pithukpakorn M
Asian Pac J Cancer Prev; 2019 Aug; 20(8):2319-2326. PubMed ID: 31450901
[TBL] [Abstract][Full Text] [Related]
12. High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma.
Garcia-Dios DA; Lambrechts D; Coenegrachts L; Vandenput I; Capoen A; Webb PM; Ferguson K; ; Akslen LA; Claes B; Vergote I; Moerman P; Van Robays J; Marcickiewicz J; Salvesen HB; Spurdle AB; Amant F
Gynecol Oncol; 2013 Feb; 128(2):327-34. PubMed ID: 23219661
[TBL] [Abstract][Full Text] [Related]
13. FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma.
Korphaisarn K; Morris VK; Overman MJ; Fogelman DR; Kee BK; Raghav KPS; Manuel S; Shureiqi I; Wolff RA; Eng C; Menter D; Hamilton SR; Kopetz S; Dasari A
Oncotarget; 2017 Jun; 8(24):39268-39279. PubMed ID: 28424412
[TBL] [Abstract][Full Text] [Related]
14. Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer.
Loree JM; Bailey AM; Johnson AM; Yu Y; Wu W; Bristow CA; Davis JS; Shaw KR; Broaddus R; Banks KC; Lanman RB; Meric-Bernstam F; Overman MJ; Kopetz S; Raghav K
J Natl Cancer Inst; 2018 Dec; 110(12):1409-1417. PubMed ID: 29718453
[TBL] [Abstract][Full Text] [Related]
15. Loss of FBXW7, a cell cycle regulating gene, in colorectal cancer: clinical significance.
Iwatsuki M; Mimori K; Ishii H; Yokobori T; Takatsuno Y; Sato T; Toh H; Onoyama I; Nakayama KI; Baba H; Mori M
Int J Cancer; 2010 Apr; 126(8):1828-1837. PubMed ID: 19739118
[TBL] [Abstract][Full Text] [Related]
16. Less frequently mutated genes in colorectal cancer: evidences from next-generation sequencing of 653 routine cases.
Malapelle U; Pisapia P; Sgariglia R; Vigliar E; Biglietto M; Carlomagno C; Giuffrè G; Bellevicine C; Troncone G
J Clin Pathol; 2016 Sep; 69(9):767-71. PubMed ID: 26797410
[TBL] [Abstract][Full Text] [Related]
17. Landscape of genomic alterations in cervical carcinomas.
Ojesina AI; Lichtenstein L; Freeman SS; Pedamallu CS; Imaz-Rosshandler I; Pugh TJ; Cherniack AD; Ambrogio L; Cibulskis K; Bertelsen B; Romero-Cordoba S; Treviño V; Vazquez-Santillan K; Guadarrama AS; Wright AA; Rosenberg MW; Duke F; Kaplan B; Wang R; Nickerson E; Walline HM; Lawrence MS; Stewart C; Carter SL; McKenna A; Rodriguez-Sanchez IP; Espinosa-Castilla M; Woie K; Bjorge L; Wik E; Halle MK; Hoivik EA; Krakstad C; Gabiño NB; Gómez-Macías GS; Valdez-Chapa LD; Garza-Rodríguez ML; Maytorena G; Vazquez J; Rodea C; Cravioto A; Cortes ML; Greulich H; Crum CP; Neuberg DS; Hidalgo-Miranda A; Escareno CR; Akslen LA; Carey TE; Vintermyr OK; Gabriel SB; Barrera-Saldaña HA; Melendez-Zajgla J; Getz G; Salvesen HB; Meyerson M
Nature; 2014 Feb; 506(7488):371-5. PubMed ID: 24390348
[TBL] [Abstract][Full Text] [Related]
18. Spatio-temporal mutation profiles of case-matched colorectal carcinomas and their metastases reveal unique de novo mutations in metachronous lung metastases by targeted next generation sequencing.
Kovaleva V; Geissler AL; Lutz L; Fritsch R; Makowiec F; Wiesemann S; Hopt UT; Passlick B; Werner M; Lassmann S
Mol Cancer; 2016 Oct; 15(1):63. PubMed ID: 27756406
[TBL] [Abstract][Full Text] [Related]
19. FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.
Jardim DL; Wheler JJ; Hess K; Tsimberidou AM; Zinner R; Janku F; Subbiah V; Naing A; Piha-Paul SA; Westin SN; Roy-Chowdhuri S; Meric-Bernstam F; Hong DS
PLoS One; 2014; 9(2):e89388. PubMed ID: 24586741
[TBL] [Abstract][Full Text] [Related]
20. TP53, PIK3CA, FBXW7 and KRAS Mutations in Esophageal Cancer Identified by Targeted Sequencing.
Zheng H; Wang Y; Tang C; Jones L; Ye H; Zhang G; Cao W; Li J; Liu L; Liu Z; Zhang C; Lou F; Liu Z; Li Y; Shi Z; Zhang J; Zhang D; Sun H; Dong H; Dong Z; Guo B; Yan HE; Lu Q; Huang X; Chen SY
Cancer Genomics Proteomics; 2016; 13(3):231-8. PubMed ID: 27107065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
